Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + lercanidipine
- Development stage
- Preclinical
- Lead developer
- Zhaoke Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvastatin + lercanidipine is a fixed-dose combination of the HMG-CoA reductase inhibitor atorvastatin and the third-generation dihydropyridine calcium channel blocker lercanidipine. It is designed to simultaneously manage hypertension and dyslipidemia, two major co-existing risk factors for cardiovascular disease. Atorvastatin works by inhibiting cholesterol synthesis in the liver, which upregulates LDL receptors and lowers circulating lipid levels. Lercanidipine relaxes vascular smooth muscle by blocking L-type calcium channels, thereby reducing peripheral vascular resistance and lowering blood pressure. The combination has been investigated in formulation patents by Zhaoke Pharmaceutical (a subsidiary of Lee's Pharmaceutical) to improve patient compliance and provide synergistic cardiovascular protection.
- Other names
- atorvastatin/lercanidipinelercanidipine + atorvastatinlercanidipine/atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LTCC (Voltage-gated calcium channel (L-type))CaV3 (Caveolin-3)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on atorvastatin + lercanidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + lercanidipine.